Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | LAP3 | P28838 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31423666 | 0.88 | ANPEP (0.37) | ANPEPLAP3ESR2PSMB5 | |
| SCHEMBL20401416 | 0.87 | ANPEP (0.42) | ANPEPLAP3F2PRSS1CYP3A4 | |
| SCHEMBL20401419 | 0.87 | ANPEP (0.42) | ANPEPLAP3F2PRSS1CYP3A4 | |
| SCHEMBL20401414 | 0.87 | ANPEP (0.42) | ANPEPLAP3F2PRSS1CYP3A4 | |
| SCHEMBL25255086 | 0.79 | ANPEP (0.34) | ANPEPLAP3F2PRSS1SIGMAR1 | |
| SCHEMBL25255081 | 0.79 | ANPEP (0.34) | ANPEPLAP3F2PRSS1SIGMAR1 | |
| SCHEMBL25255083 | 0.79 | ANPEP (0.34) | ANPEPLAP3F2PRSS1SIGMAR1 | |
| SCHEMBL31423729 | 0.79 | PSMB5 (0.38) | ANPEPLAP3PSMB5 | |
| SCHEMBL26692139 | 0.79 | PSMB5 (0.38) | ANPEPLAP3PSMB5 | |
| SCHEMBL26692146 | 0.79 | PSMB5 (0.38) | ANPEPLAP3PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346613-A1 | BORIC ACID PROTEASOME INHIBITOR AND USE THEREOF | ARTIVILA BIOPHARMA (CN) | 2025-11-13 | — | — | US | disclosed |
| EP-4516796-A1 | BORIC ACID PROTEASOME INHIBITOR AND USE THEREOF | Artivila Biopharma (CN) | 2025-03-05 | — | — | EP | disclosed |
| CN-117003776-A | Boric acid proteasome inhibitor and application thereof | 科辉智药生物科技(深圳)有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20190055267-A1 | ORGANOTRIFLUOROBORATE MIMICS OF AMINO ACIDS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN (US) | 2019-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055267-A1 | ORGANOTRIFLUOROBORATE MIMICS OF AMINO ACIDS AND USES THEREOF | SLC1A5, SLC43A1, BCAT2 | ANPEP 191/4885LAP3 157/4885F2 1226/4885 |
| US-20250346613-A1 | BORIC ACID PROTEASOME INHIBITOR AND USE THEREOF | PSMA1, PSMB11, PSMB1 | ANPEP 1400/4885LAP3 1238/4885F2 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.